GGrantIndex
Sort

40,608 grants matching prostate cancer

The aberrant androgen receptor underlies abiraterone/enzalutamide resistance

$370,575
Jun Luo · Johns Hopkins University · R01 · FY2017 · CA

Development of small molecules for ERG ablation in prostate cancer

$370,575
Ralf Kittler · Ut Southwestern Medical Center · R01 · FY2018 · CA

Targeting m6A RNA epigenetics in treatment-emergent neuroendocrine prostate cancer

$370,575
Min Sup Song · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA

Studies of the Antifungal Drug Itraconazole As A Novel Inhibitor of Angiogenesis

$370,575
Jun O. Liu · Johns Hopkins University · R01 · FY2015 · CA

Development of small molecules for ERG ablation in prostate cancer

$370,575
Ralf Kittler · Ut Southwestern Medical Center · R01 · FY2020 · CA

The aberrant androgen receptor underlies abiraterone/enzalutamide resistance

$370,575
Jun Luo · Johns Hopkins University · R01 · FY2016 · CA

Cis-aconitate decarboxylase (ACOD1) in PMN-MDSC and prostate cancer progression

$370,575
Guocan Wang · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA

Role of MED1 in the AR-dependent transcription in advanced prostate cancer

$370,575
Irfan Ahmed Asangani · University Of Pennsylvania · R01 · FY2020 · CA

The aberrant androgen receptor underlies abiraterone/enzalutamide resistance

$370,575
Jun Luo · Johns Hopkins University · R01 · FY2018 · CA

Managed Care Penetration and Cancer Care

$370,556
Harvard University (Medical School) · R01 · FY2002 · CA

Dissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesis

$370,552
Edward L Schwartz · Albert Einstein College Of Medicine · R01 · FY2019 · CA

Project 2: Targeting DNA replication in BRCA-associated breast cancer

$370,550
Bing Xia · Rbhs -Cancer Institute Of New Jersey · P01 · FY2021 · CA

Project 4: Identification of Essential Genes Underlying AR Activity in Antagonist-Resistant CRPC

$370,489
Myles A Brown · Beth Israel Deaconess Medical Center · P01 · FY2022 · CA

Interactions and Functions of p14ARF in Cancer

$370,484
Ruth A Gjerset · Sidney Kimmel Cancer Center · R01 · FY2008 · CA

Interactions and Functions of p14ARF in Cancer

$370,484
Ruth A Gjerset · Sidney Kimmel Cancer Center · R01 · FY2007 · CA

Parp Function in Prostate Cancer

$370,478
Bryce M Paschal · University Of Virginia · R01 · FY2017 · CA

Dissecting mechanisms of sensitivity to B7-H3 (CD276)-targeted therapeutics in prostate cancer (PC)

$370,476
Justin H. Hwang · University Of Minnesota · R37 · FY2024 · CA

Basic Cancer Research in Cancer Health Disparities

$370,462
Radoslav Goldman · Georgetown University · U01 · FY2012 · CA

3-way approach for ED prevention

$370,459
Carol Ann Podlasek · University Of Illinois At Chicago · R01 · FY2018 · DK

Role of alpha6 beta1 Integrin in Prostate Cancer

$370,449
Cynthia K Miranti · Van Andel Research Institute · R01 · FY2014 · CA

The B7x pathways in the tumor microenvironment

$370,440
Xingxing Zang · Albert Einstein College Of Medicine · R01 · FY2023 · CA

Selenium molecular signaling in human prostate cancer

$370,417
Roswell Park Cancer Institute Corp · R01 · FY2004 · CA

Hemostasis System in Tumor Growth and Metastasis

$370,415
Victoria Ploplis · University Of Notre Dame · P01 · FY2008 · HL

Targeting the colchicine binding site in tubulin for cancer therapy

$370,326
Wei Li · University Of Tennessee Health Sci Ctr · R01 · FY2024 · CA

Sonic hedgehog:Insulin-Like Growth Factor Interactions in Proliferating Neural Pr

$370,321
Anna Marie Kenney · Sloan-Kettering Inst Can Research · R01 · FY2010 · NS